Morrisville, NC – August 2026 — MAA Laboratories, Inc. today announced that it has received written regulatory feedback from Brazil’s National Health Surveillance Agency (ANVISA) regarding the development of a product utilizing the Company’s proprietary NanoCont™ technology.

The advice supports MAA’s ongoing development efforts and provides regulatory clarity for advancing NanoCont™-enabled products in Brazil. Importantly, the feedback from ANVISA is consistent with regulatory guidance previously received from the U.S. Food and Drug Administration (FDA), the Federal Institute for Drugs and Medical Devices (BfArM) in Germany, Health Canada, and Australia’s Therapeutic Goods Administration (TGA), further strengthening the global regulatory alignment for MAA’s NanoCont™ product development strategy.

“The regulatory alignment we have now achieved across the U.S., Europe, Canada, Australia, and Brazil provides strong validation for our regulatory and clinical approach and reinforces our confidence in the global potential of the NanoCont™ platform,” said Dr. Anjani Jha, CEO of MAA Laboratories.

MAA Laboratories remains committed to advancing differentiated therapies through its NanoCont™ platform and expanding its pipeline across global markets.

For press and other inquiries, please contact:
Email: info@maalaboratories.com
Phone: +1 (919)271.7868